Livzon Pharmaceutical Group Inc (000513) - Total Liabilities
Based on the latest financial reports, Livzon Pharmaceutical Group Inc (000513) has total liabilities worth CN¥8.61 Billion CNY (≈ $1.26 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Livzon Pharmaceutical Group Inc to see how much of total assets are deployed in long-term investments.
Livzon Pharmaceutical Group Inc - Total Liabilities Trend (1992–2025)
This chart illustrates how Livzon Pharmaceutical Group Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Livzon Pharmaceutical Group Inc.
Livzon Pharmaceutical Group Inc Competitors by Total Liabilities
The table below lists competitors of Livzon Pharmaceutical Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Doosan Fuel Cell Co Ltd
KO:336260
|
Korea | ₩1.04 Trillion |
|
Hanesbrands Inc
NYSE:HBI
|
USA | $3.83 Billion |
|
Primarius Technologies Co. Ltd. A
SHG:688206
|
China | CN¥436.31 Million |
|
GQG Partners Inc
AU:GQG
|
Australia | AU$61.28 Million |
|
By health
SHE:300146
|
China | CN¥2.60 Billion |
|
Liveramp Holdings Inc
NYSE:RAMP
|
USA | $301.41 Million |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX65.80 Billion |
|
Pengxin International Mining Co Ltd
SHG:600490
|
China | CN¥1.77 Billion |
Liability Composition Analysis (1992–2025)
This chart breaks down Livzon Pharmaceutical Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Livzon Pharmaceutical Group Inc (000513) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Livzon Pharmaceutical Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Livzon Pharmaceutical Group Inc (1992–2025)
The table below shows the annual total liabilities of Livzon Pharmaceutical Group Inc from 1992 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥8.20 Billion ≈ $1.20 Billion |
-14.17% |
| 2024-12-31 | CN¥9.55 Billion ≈ $1.40 Billion |
-7.08% |
| 2023-12-31 | CN¥10.28 Billion ≈ $1.50 Billion |
+3.49% |
| 2022-12-31 | CN¥9.93 Billion ≈ $1.45 Billion |
+23.21% |
| 2021-12-31 | CN¥8.06 Billion ≈ $1.18 Billion |
+15.97% |
| 2020-12-31 | CN¥6.95 Billion ≈ $1.02 Billion |
+21.92% |
| 2019-12-31 | CN¥5.70 Billion ≈ $834.27 Million |
+0.24% |
| 2018-12-31 | CN¥5.69 Billion ≈ $832.26 Million |
+21.94% |
| 2017-12-31 | CN¥4.66 Billion ≈ $682.51 Million |
+36.23% |
| 2016-12-31 | CN¥3.42 Billion ≈ $500.98 Million |
+4.77% |
| 2015-12-31 | CN¥3.27 Billion ≈ $478.16 Million |
+1.47% |
| 2014-12-31 | CN¥3.22 Billion ≈ $471.21 Million |
+8.74% |
| 2013-12-31 | CN¥2.96 Billion ≈ $433.36 Million |
+20.70% |
| 2012-12-31 | CN¥2.45 Billion ≈ $359.04 Million |
+54.19% |
| 2011-12-31 | CN¥1.59 Billion ≈ $232.86 Million |
+55.58% |
| 2010-12-31 | CN¥1.02 Billion ≈ $149.67 Million |
+13.79% |
| 2009-12-31 | CN¥898.92 Million ≈ $131.54 Million |
-17.48% |
| 2008-12-31 | CN¥1.09 Billion ≈ $159.40 Million |
+14.09% |
| 2007-12-31 | CN¥954.80 Million ≈ $139.72 Million |
-11.31% |
| 2006-12-31 | CN¥1.08 Billion ≈ $157.53 Million |
+16.36% |
| 2005-12-31 | CN¥925.20 Million ≈ $135.39 Million |
-10.17% |
| 2004-12-31 | CN¥1.03 Billion ≈ $150.72 Million |
+7.88% |
| 2003-12-31 | CN¥954.70 Million ≈ $139.70 Million |
+31.31% |
| 2002-12-31 | CN¥727.05 Million ≈ $106.39 Million |
+13.71% |
| 2001-12-31 | CN¥639.37 Million ≈ $93.56 Million |
+10.00% |
| 2000-12-31 | CN¥581.24 Million ≈ $85.05 Million |
-0.46% |
| 1999-12-31 | CN¥583.95 Million ≈ $85.45 Million |
+24.88% |
| 1998-12-31 | CN¥467.61 Million ≈ $68.43 Million |
-1.45% |
| 1997-12-31 | CN¥474.51 Million ≈ $69.44 Million |
-13.27% |
| 1996-12-31 | CN¥547.10 Million ≈ $80.06 Million |
+22.26% |
| 1995-12-31 | CN¥447.49 Million ≈ $65.48 Million |
+81.43% |
| 1994-12-31 | CN¥246.65 Million ≈ $36.09 Million |
-1.58% |
| 1993-12-31 | CN¥250.60 Million ≈ $36.67 Million |
-21.37% |
| 1992-12-31 | CN¥318.71 Million ≈ $46.64 Million |
-- |
About Livzon Pharmaceutical Group Inc
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more